glp-1 news 2025 october 21 Perspectives from Employers on the Costs and Issues Associated with Covering GLP-1 Agonists for Weight Loss 1 in 10 Americans Has

It is critical to avoid freezing these medications, as freezing damages the molecular structure of the active ingredient, rendering the medication ineffective

Case Presentation The patient is a 79-year-old former business owner and stockbroker

I know Retatrutide is not officially approved yet, but for me, waiting was not an option

Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease

Primers sequences are listed in Table 1

These medications are rewriting the weight loss narrative by offering science-backed, sustainable solutions for those struggling with obesity or excess weight